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Introduction: In WAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-Up
Stroke), patients with an acute stroke of unknown onset time were randomized to
treatment with intravenous alteplase or placebo, guided by MRI.
Methods: In this exploratory post-hoc secondary analysis we compared clinical and
imaging data, as well as treatment effects and safety of intravenous thrombolysis
between patients with infra- vs. supratentorial stroke.
Results: Forty-eight out of 503 randomized patients (9.5%) presented with a stroke
involving the cerebellum or brainstem. Patients with infratentorial stroke were younger
compared to patients with supratentorial stroke (mean age 60 vs. 66 years), more
frequently male (85 vs. 62%), and less severely affected (median NIHSS 4.5 vs. 6.0).
There was no heterogeneity for treatment effect between supratentorial (OR 1.67 95% CI
1.11–2.51) and infratentorial (OR 1.31 95% CI 0.41–4.22) sub-groups (test for interaction
p = 0.70). In patients with infratentorial stroke, favorable outcome [a score of 0–1 on
the modified Rankin scale (mRS) at 90 days] was observed in 12/22 patients (54.5%)
in the alteplase group and in 13/25 patients (52.0%) in the placebo group (p = 0.59).
The primary safety endpoint (death or mRS 4–6 at day 90) occurred in three patients of
the alteplase group (13.6%) and three patients in the placebo group (12.0%); p = 0.74.
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Discussion: WAKE-UP was underpowered for demonstrating treatment effect in
subgroup analyses however, based on our current results, there is no evidence to
recommend withholding MRI-guided thrombolysis in patients with unknown onset stroke
of infratentorial localization.
Keywords: infratentorial infarct, infratentorial stroke, intravenous thrombolysis, alteplase, MRI, WAKE-UP
INTRODUCTION
The WAKE-UP trial (a randomized, double-blind, placebo-
controlled trial, ClinicalTrials.gov number, NCT01525290) (1)
was an investigator-initiated, multicenter, randomized, double-
blind, placebo-controlled clinical trial which provided evidence
of clinical benefit of MRI-guided treatment with intravenous
alteplase in acute stroke patients with an unknown time of
symptom onset. The study was based on the concept of DWI-
FLAIR mismatch, with lesions visible on diffusion-weighted
imaging (DWI) but not clearly visible on fluid-attenuated-
inversion-recovery (FLAIR) identifying patients within 4.5 h of
stroke onset. This concept was established through previous
studies reporting a high specificity (78%) and positive predictive
value (83%) of the DWI-FLAIR mismatch in identifying
hyperacute stroke patients (2). Since previous studies have
shown that FLAIR signal changes might develop more slowly in
infratentorial than in supratentorial stroke (3, 4), there remained
uncertainty about the safety and efficacy of thrombolysis based
on DWI-FLAIR mismatch in this cohort. In WAKE-UP, patients
were randomized irrespective of the localization of the acute
ischemic stroke, providing us with an opportunity to perform
a subgroup analysis of patients with brainstem and cerebellar
strokes. The objective of the current study was to investigate the
safety and efficacy of intravenous alteplase administered based




The national competent authorities and ethics committees in
all participating countries approved the study. WAKE-UP was
registered at https://www.clinicaltrials.gov. Unique identifier:
NCT01525290. URL: https://www.clinicaltrialsregister.eu.
Unique identifier: 2011-005906-32. Informed consent
was obtained from all patients prior to enrollment into
the trial. Patients were included in this substudy if the
sole location of their acute ischemic lesion (based on
baseline DWI) was in one or more of the following brain
regions: the pons, medulla oblongata, cerebellum, or
mesencephalon. We examined demographic characteristics,
clinical, and imaging data at baseline and follow-ups for this
subgroup of patients and compared them to patients with
a supratentorial stroke.
Outcome Measures
The primary efficacy endpoint was favorable outcome defined
as a score of 0–1 on the modified Rankin scale (mRS) at
final follow up (90 days post-stroke). As a secondary efficacy
endpoint we evaluated an ordinal analysis of the mRS (“shift
analysis”). The primary safety endpoint was death or dependence
(defined as a score of 4–6 on the mRS at 90 days post-stroke),
additional safety outcomes were the incidence of symptomatic
intracerebral hemorrhage (SICH) according to the protocols of
SITS-MOST, ECASS II, ECASS III, NINDS, and parenchymal
hemorrhage type 2 (PH-2) on follow-up imaging 22–36 h after
treatment (5–8).
Statistical Analysis
Statistical analyses of treatment effects were performed in the
intention-to-treat population. To investigate the interaction
between stroke location (i.e., infra- vs. supratentorial lesion)
and treatment effect on the primary endpoint, we used an
unconditional logistic regression model, relating the log-odds of
the primary outcome with the covariate of interest, the treatment
group, and their interaction. The interaction termwas tested with
the Wald-Chi-squared test, and the treatment effect (odds ratio
[OR]) and its 95% confidence interval (CI) was estimated for
each category of the stroke location. We furthermore repeated
the analysis of primary and secondary endpoints as in the original
trial analysis in the subpopulation of patients with infratentorial
strokes. The main efficacy variable as well as the safety endpoints
were assessed using an unconditional logistic regression analysis,
fitted to estimate the OR and its 95% CI interval. The categorical
shift in the distribution of mRS scores was analyzed by fitting a
proportional-odds logistic regression model. All analyses were
adjusted for the stratification parameters age and NIHSS. All
tests were carried out with a two-sided alpha level of 5% without
correction for multiple comparisons.
RESULTS
Comparison of Infra- vs. Supratentorial
Strokes in the Screened Population
Of 1,362 patients screened for WAKE-UP, 84 (6%) had a
cerebellar and/or brainstem stroke. These patients were younger
(mean 62.5 years, SD 12.0) when compared to patients
with supratentorial strokes (mean 65.3 years, SD 11.8; p =
0.02), and were more often male (64/84, 76% as opposed to
769/1,278, 60%; p = 0.004). In addition, the NIHSS score at
baseline (median; IQR) was lower in patients with infratentorial
stroke (5; 3–6) than in patients with supratentorial stroke
(6; 4–11), p < 0.001. We did not identify a difference in
cardiovascular risk factors e.g., arterial hypertension, diabetes
mellitus, hypercholesterolemia, or history of ischemic stroke
between groups. However, there was a higher prevalence of atrial
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FIGURE 1 | Examples of infratentorial strokes in the intention-to-treat WAKE-UP cohort. The upper row shows diffusion-weighted images depicting the acute
ischemic stroke. The bottom row shows a FLAIR image of the corresponding slice, depicting a lack of signal hyperintensity in the area of the acute stroke. The
different columns offer examples for the different stroke locations included into this substudy: (A) depicts a stroke of the ventral left portion of the medulla oblongata,
(B) a right-sided cerebellar stroke in the feeding territory of the superior cerebellar artery, (C) a right-sided stroke in the pons, and (D) a focal mesencephalic stroke.
TABLE 1 | Group comparison between patients with an infra- and a supratentorial







Mean age (years) (SD) 65.8 (11.3) 59.9 (12.2) p < 0.001
Gender (male), N (%) 284 (62.4%) 41 (85.4%) p = 0.001
Median symptom recognition to
start of treatment (hours) (IQR)
3.1 (2.5–3.9) 3.2 (2.7–3.9) p = 0.227
Arterial hypertension, N (%) 241 (53.0%) 25 (52.1%) p = 0.912
Diabetes mellitus, N (%) 72 (15.8%) 10 (20.8%) p = 0.680
Atrial fibrillation, N (%) 58 (12.8%) 1 (2.1%) p = 0.049
Hypercholesterolemia, N (%) 160 (35.2%) 18 (37.2%) p = 0.387
Median NIHSS at baseline (IQR) 6.0 (4.0–10.0) 4.5 (3.0–6.0) p = 0.001
Median NIHSS at 7 days
post-stroke (IQR)
2.0 (1.0–6.0) 2.0 (0.0–6.0) p = 0.156
Median stroke volume at baseline
(ml) (IQR)
2.6 (0.9–9.6) 0.8 (0.3–1.8) p < 0.001
Median stroke volume at follow up
(ml) (IQR)
3.5 (1.1–19.5) 0.8 (0.3–3.1) p < 0.001
Follow up was 22–36 h after treatment.
fibrillation in patients with supratentorial strokes (106/1,278, 8%)
as compared to patients with infratentorial strokes (1/84, 1%; p
= 0.03). In infratentorial stroke patients, there were numerically
fewer FLAIR positive lesions compared to the group with a
supratentorial stroke localization (23/84, 27% as opposed to
479/1,278, 38%; p= 0.09).
Comparison of Infra- vs. Supratentorial
Strokes in the Intention-to-Treat
Population
Of the 503 patients who were randomized into the trial, 48
(9.5%) presented with a stroke in an infratentorial brain region.
Twenty-six patients (54%) were assigned to placebo with one
patient not having received infusion and 22 patients received
alteplase (46%). Twenty-eight patients had an ischemic lesion
in the pons (58%), nine patients had cerebellar stroke (19%),
seven patients presented with an infarct in the medulla oblongata
(15%), two patients had a stroke in the mesencephalon (4%),
and two patients (4%) had strokes in more than one location
(brainstem plus cerebellum); see Figure 1 for examples. The
distribution of lesion localization was extremely uniform between
the placebo and the alteplase group. As in the overall screened
population, patients randomized with infratentorial strokes were
also younger, more often male and less severely affected at
admission to hospital than those with supratentorial strokes
(Table 1). However, at day 7 post-stroke, there was no longer a
difference in the NIHSS scores between the groups (Table 1). As
expected, the median baseline volume of infratentorial strokes
was smaller than that of supratentorial strokes (0.8 vs. 2.6ml;
p < 0.001). There was no statistically significant difference in
the percentage of patients reaching the primary efficacy endpoint
in infratentorial stroke (25/47, 53%) vs. supratentorial stroke
(208/443, 47%); p = 0.45. In addition, the rate of reaching the
primary safety endpoint did not differ, with 6/47 (13%) patients
in the infratentorial group and 72/443 (16%) patients in the
supratentorial group (p = 0.23). There were no symptomatic
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FIGURE 2 | Forest plots depicting the effect (adjusted OR) of alteplase on favorable outcome in patients with a supra- and infratentorial stroke with no evidence of a
significant interaction between stroke localization and treatment effect.
intracerebral hemorrhages in the infratentorial patient group
and only three patients experienced petechial hemorrhagic
transformation (HI-1 and HI-2) (6%, as compared to 73/455 or
16% in the supratentorial group).
Treatment with alteplase was associated with higher odds of
favorable outcome with no significant heterogeneity of treatment
effect for stroke subtype (infratentorial vs. supratentorial). The
adjusted OR for favorable outcome with alteplase was 1.31 (95%
CI 0.41–4.22) in patients with infratentorial infarct and 1.67 (95%
CI 1.11–2.51) in patients with supratentorial infarct (test for
interaction, p= 0.70; see Figure 2).
Results in the Subpopulation of
Infratentorial Strokes
Baseline parameters were comparable for patients randomized to
receiving alteplase or placebo (Table 2). Favorable outcome was
observed in 12 out of 22 patients (55%) in the alteplase group
and in 13 out of 25 patients (52%) in the placebo group (adjusted
OR, 1.38; 95% CI 0.42–4.56; p = 0.60). The 90 day distributions
of mRS scores for the remaining categories were, for the alteplase
and the placebo arm, respectively, five patients (23%) vs. seven
patients (28%) with mRS of 2, two patients each (9 vs. 8%) for
mRS of 3, two patients (9%) vs. one patient (4%) for mRS of 4 and
one patient (5%) vs. two patients (8%) with an mRS of 5 or 6. We
were unable to show a trend for a shift toward better outcomes
in those infratentorial stroke patients treated with alteplase as
compared to those who received placebo (adjusted common OR
1.19; 95% CI 0.41–3.42; p= 0.75). There were no SICH or deaths
in the group of patients with infratentorial strokes, regardless of
the administered treatment. The primary safety endpoint (death
or mRS score 4–6 at day 90) occurred in three patients of the
alteplase group (14%) and three patients in the placebo group
(12%); p= 0.74. Petechial hemorrhagic transformation (HI-1 and
HI-2) occurred in two patients (9%) who have received alteplase
and one patient (4%) who received placebo (p= 0.59).
DISCUSSION
WAKE-UP demonstrated a clear clinical benefit of treatment
with intravenous alteplase in patients with an acute ischemic
lesion visible on DWI but not yet evidently visible on FLAIR
TABLE 2 | Comparison between patients who received alteplase and those who





Mean age (years) (SD) 62.6 (10.3) 57.7 (13.5) p = 0.230
Gender (male), N (%) 20 (90.9%) 21 (80.8%) p = 0.429
Median symptom recognition to
start of treatment (hours) (IQR)
3.1 (2.6–3.6) 3.5 (2.9–4.0) p = 0.272
Arterial hypertension, N (%) 12 (54.6%) 13 (50.0%) p = 0.780
Diabetes mellitus, N (%) 7 (31.8%) 3 (11.5%) p = 0.152
Atrial fibrillation, N (%) 1 (4.6%) 0 (0.0%) p = 0.205
Hypercholesterolemia, N (%) 11 (50.0%) 7 (26.9%) p = 0.138
Median NIHSS at baseline (IQR) 5.0 (3.0–8.0) 4.0 (3.0–5.0) p = 0.295
Median NIHSS at 7 days
post-stroke (IQR)
1.5 (0.0–6.0) 2.0 (1.0–4.0) p = 0.580
Median stroke volume at baseline
(ml) (IQR)
0.8 (0.2–1.9) 0.7 (0.3–1.3) p = 0.820
Median stroke volume at follow up
(ml) (IQR)
0.8 (0.3–3.1) 0.9 (0.4–3.1) p = 0.656
Follow up was 22–36 h after treatment.
imaging. In this secondary post hoc analysis, we focused
on the treatment effect and further elucidated the clinical
characteristics and outcome in a subpopulation of WAKE-
UP patients with a brainstem or cerebellar DWI lesion. We
did not observe heterogeneity of the treatment effect based
on stroke localization. There was no difference in death
or dependence between the two treatment arms and no
symptomatic intracerebral hemorrhages occurred in our cohort
of patients with infratentorial ischemic lesions. Thus, we do
not recommend excluding patients with infratentorial stroke of
unknown time of symptom onset with a DWI/FLAIR mismatch
from intravenous thrombolysis. However, the analysis was unable
to prove benefit of thrombolysis in the alteplase arm, presumably
due to the fact that the trial was underpowered to demonstrate
superiority in this context. An additional limitation of the study
was the inclusion of patients with relatively mild strokes, making
the generalization of the findings on patients suffering severe
stroke difficult.
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There were some clinical differences between the subgroups.
Infratentorial stroke patients were younger and more frequently
male as compared to patients with supratentorial stroke, which
corresponds to trends reported in literature (4, 9). They also had
lower baseline NIHSS scores and smaller stroke volumes, results
which are logical and equally in line with previous observations
(4, 9). The higher prevalence of atrial fibrillation in patients
with supratentorial as opposed to infratentorial stroke, as found
in our study, has similarly been previously reported (9). These
findings could in part be explained by the younger age and
male predominance in our cohort, as there is a known higher
prevalence of atrial fibrillation in older women leading to an
increased risk of severe cardioembolic strokes in the anterior
circulation in females (10).
In the context of stroke of unknown onset, previous research
has shown that ischemic lesions in infratentorial brain regions
likely take longer to develop a FLAIR hyperintense signal
(4) which subsequently implies that a proportion of patients
treated based on the presence of a DWI-FLAIR mismatch
are likely beyond the conventional 4.5 h time window for
rt-PA. Justifiably, at the time of the study’s conduct, this
raised potential safety concerns. Our current analysis suggests
that these concerns were unfounded as no deaths and no
parenchymal hemorrhages (symptomatic or otherwise) occurred
in our subgroup of patients with infratentorial strokes. This
may in part be the effect of the mild stroke severity in our
cohort, but is also in line with previous large cohort studies
which have reported very low SICH rates in patients with
isolated brainstem and cerebellar strokes (9, 11). Also befitting
the literature (9, 11), the percentage of observed hemorrhagic
transformations was lower in the subgroup of infratentorial as
compared to supratentorial stroke patients, which comes to no
surprise as it is often not associated with thrombolysis but rather
dependent on stroke size and severity (12). This underlines the
safety of patient selection for intravenous thrombolysis based
on the DWI-FLAIR mismatch approach in infratentorial, mild
to moderate stroke. Some previous studies have pointed to a
lesser importance of the time to treatment (with regards to
developing intracranial hemorrhage or unfavorable outcome) in
posterior circulation strokes as compared to anterior circulation
strokes (13). However, it is also conceivable that the stage
of tissue damage depicted by a positive DWI but negative
FLAIR signifies a condition in which thrombolysis is still
safe, irrespective of the actual time which elapsed since the
onset of ischemia. Other recent studies have equally pointed
to the safety (as well as efficacy) of acute stroke treatment in
the unknown and extended time window in carefully selected
patient cohorts, further moving evidence away from time-
based and toward tissue-based models and individually tailored
therapy (14).
Our analysis did not show a difference between rt-PA and
placebo on the treatment effect in patients with unknown onset
stroke of infratentorial localization. There is a general lack
of information on this subject in the literature, as very few
randomized, controlled trials or phase IV studies evaluating the
safety and efficacy of iv tPA in posterior circulation strokes are
available (15, 16). Hence our findings, notwithstanding the small
cohort size, represent knowledge novel and relevant to the field.
Within the WAKE-UP study population itself, the percentage
of infratentorial alteplase treated patients who reached favorable
outcome was slightly higher than in the overall study cohort
(54.5 vs. 53.3%) but the placebo group of infratentorial patients
did remarkably well with 52% reaching favorable outcome (as
opposed to only 41.8% of patients in the complete WAKE-UP
population). This is not surprising as some preexisting studies
have shown that up to 60% of patients with a stroke in the
posterior circulation recover to the point of being able to carry
out all usual duties and activities despite lack of treatment (16).
This same study (16) identified a cutoff baseline NIHSS score
of 5 or below as one with a high sensitivity and specificity
for predicting favorable outcome in untreated patients with a
posterior circulation stroke (and 75% of the placebo cohort in
our current substudy had a baseline NIHSS of 5 or less). Hence,
a high response rate in the placebo group of our study was to
be expected, a fact which has arguably undermined the potential
to detect treatment effect in some other previously conducted
trials (17).
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